"IMMUNOL LETT 2019 10.1016/j.imlet.2019.10.005
A combination regimen of low-dose bortezomib and rapamycin prolonged the graft survival in a murine allogeneic islet transplantation model
Hong1, SH; Kim, K; Shin, JS; Chung, H; Park, CG

BONE MARROW TRANSPL 2019 10.1038/s41409-019-0629-7
Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
Lee1, YJ; Moon, JH; Sohn, SK; Kim, SJ; Jung, SH; Lee, JJ; Jo, JC; Shin, HJ; Lee, WS; Lee, JH; Bae, SH; Kim, MK; Lee, HS; Kim, K; Min, CK

Blood Cancer J 2019 10.1038/s41408-019-0245-1
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network
Soekojo1, CY; Kim, K; Huang, SY; Chim, CS; Takezako, N; Asaoku, H; Kimura, H; Kosugi, H; Sakamoto, J; Gopalakrishnan, SK; Nagarajan, C; Wei, Y; Moorakonda, R; Lee, SL; Lee, JJ; Yoon, SS; Kim, JS; Min, CK; Lee, JH; Durie, B; Chng, WJ

J CLIN APHERESIS 2019 10.1002/jca.21734
Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma
Park1, Y; Kim, DS; Jeon, MJ; Lee, BH; Yu, ES; Kang, KW; Lee, SR; Sung, HJ; Nam, MH; Yoon, SY; Choi, CW; Kang, ES; Cho, D; Kim, K; Kim, BS; Kim, DW; Kim, SJ

EUR J CANCER CARE 2019 10.1111/ecc.13089
Influence of time lapse after cancer diagnosis on the association between unmet needs and quality of life in family caregivers of Korean cancer patients
Shin1, J; Ko, H; Lee, JW; Kim, K; Song, YM

SCI REP-UK 2019 10.1038/s41598-019-48513-6
Prognostic values of novel biomarkers in patients with AL amyloidosis
Kim1, D; Lee, G; Choi, JO; Kim, K; Kim, S; Ju, ES; Jeon, ES

BIOL BLOOD MARROW TR 2019 10.1016/j.bbmt.2019.03.016
A Phase I/II Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study
Park1, SS; Kim, K; Kim, SJ; Lee, JH; Yoon, SS; Mun, YC; Lee, JJ; Eom, HS; Kim, JS; Min, CK

SCI REP-UK 2019 10.1038/s41598-019-44245-9
Associations of Electrocardiographic Parameters with Left Ventricular Longitudinal Strain and Prognosis in Cardiac Light Chain Amyloidosis
Kim1, D; Lee, GY; Choi, JO; Kim, K; Kim, SJ; Jeon, ES

ANN HEMATOL 2019 10.1007/s00277-019-03602-4
Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries
Hungria1, VTM; Lee, JH; Maiolino, A; Crusoe, ED; Martinez, G; Bittencourt, R; Duarte, GO; Fantl, DB; Navarro, JR; Conte, G; Gomez-Almaguer, D; Ruiz-Arguelles, GJ; Kim, K; Shimizu, K; Chen, WM; Huang, SY; Chng, WJ; Chim, CS; Nawarawong, W; Durie, B

Oncoimmunology 2019 10.1080/2162402X.2018.1544442
PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer
Angell1, HK; Lee, J; Kim, KM; Kim, K; Kim, ST; Park, SH; Kang, WK; Sharpe, A; Ogden, J; Davenport, A; Hodgson, DR; Barrett, JC; Kilgour, E

JPN J CLIN ONCOL 2019 10.1093/jjco/hyy177
Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice
Park1, SS; Eom, HS; Kim, JS; Koh, Y; Choi, CW; Lee, JJ; Kim, K; Suh, C; Lee, JH; Min, CK

INT J HEMATOL 2019 10.1007/s12185-018-2540-1
Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone
Shin1, J; Lee, JJ; Kim, K; Min, CK; Lee, JO; Suh, C; Kim, JS; Lee, YJ; Yoon, SS; Jo, JC; Lee, HS; Bang, SM; Lee, JO; Bang, SM; Lee, JJ; Kim, K; Min, CK; Suh, C; Yoon, DH; Kim, JS; Lee, YJ; Moon, JH; Yoon, SS; Kim, I; Jo, JC; Lee, HS; Park, SK; Shin, HJ; Kim, MK; Mun, YC; Lee, MH; Park, Y; Eom, HS; Kim, HJ; Im, SN; Kim, SH; Do, YR; Lee, WS; Cho, SH; Yi, JH; Lee, JH

ANN LAB MED 2019 10.3343/alm.2019.39.1.96
First Case of Plasma Cell Myeloma With Brown Tumor Features Unrelated to Hyperparathyroidism
Kim1, H; Kim, K; Cho, SR; Kim, HJ; Kim, SH

J CLIN MICROBIOL 2018 10.1128/JCM.00438-18
Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients
Ryu1, MR; Park, MS; Cho, EH; Jung, CW; Kim, K; Kim, SJ; Oh, HY; Huh, W; Jang, HR; Koh, WJ; Park, HY; Kim, YH; Sinn, DH; Choi, JO; Joh, JW; Kim, JM; Kim, SJ; Park, JB; Kang, ES

ACTA HAEMATOL-BASEL 2018 10.1159/000490488
The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma
Lee1, GW; Park, SW; Go, SI; Kim, HG; Kim, MK; Min, CK; Kwak, JY; Bae, SB; Yoon, SS; Lee, JJ; Kim, KH; Nam, SH; Mun, YC; Kim, HJ; Bae, SH; Shin, HJ; Lee, JH; Park, JS; Jeong, SH; Lee, MH; Lee, HS; Park, KW; Lee, WS; Lee, SM; Lee, JO; Hyun, MS; Jo, DY; Lim, SN; Lee, JH; Kim, H; Cho, DY; Do, YR; Kim, JA; Park, SK; Kim, JS; Kim, SJ; Yi, HG; Moon, JH; Choi, CW; Kim, SH; Kim, BS; Park, MR; Shim, H; Song, MK; Kim, Y; Kim, K

HAEMATOL-HEMATOL J 2018 10.3324/haematol.2018.194282
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
Dimopoulos1, MA; San-Miguel, J; Belch, A; White, D; Benboubker, L; Cook, G; Leiba, M; Morton, J; Ho, PJ; Kim, K; Takezako, N; Moreau, P; Kaufman, JL; Sutherland, HJ; Lalancette, M; Magen, H; Iida, S; Kim, JS; Prince, HM; Cochrane, T; Oriol, A; Bahlis, NJ; Chari, A; O'Rourke, L; Wu, K; Schecter, JM; Casneuf, T; Chiu, C; Soong, D; Sasser, AK; Khokhar, NZ; Avet-Loiseau, H; Usmani, SZ

LEUKEMIA LYMPHOMA 2018 10.1080/10428194.2018.1427858
Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop
Tan1, D; Lee, JH; Chen, WM; Shimizu, K; Hou, J; Suzuki, K; Nawarawong, W; Huang, SY; Chim, CS; Kim, K; Kumar, L; Malhotra, P; Chng, WJ; Durie, B

BONE MARROW TRANSPL 2018 10.1038/s41409-018-0097-5
Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study
Yoo1, KH; Kang, D; Kim, IR; Choi, EK; Kim, JS; Yoon, SS; Lee, CH; Park, S; Kim, SJ; Kim, K; Kim, WS; Jung, CW; Choi, HJ; Jang, JH; Cho, J

GENOME RES 2018 10.1101/gr.228080.117
Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data
Fan1, J; Lee, HO; Lee, S; Ryu, DE; Lee, S; Xue, C; Kim, SJ; Kim, K; Barkas, N; Park, PJ; Park, WY; Kharchenko, PV

BRIT J HAEMATOL 2018 10.1111/bjh.14701
A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System
Jung1, SH; Kim, K; Kim, JS; Kim, SJ; Cheong, JW; Kim, SJ; Ahn, JS; Ahn, SY; Yang, DH; Kim, HJ; Lee, JJ

PROTEOM CLIN APPL 2018 10.1002/prca.201700106
Development and Validation of Mass Spectrometry-Based Targeted Analysis for Amyloid Proteins
Park1, J; Lee, GY; Choi, JO; Jeon, ES; Kim, K; Kim, JS; Lee, SY

BIOL BLOOD MARROW TR 2018 10.1016/j.bbmt.2018.01.004
Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)
Jung1, SH; Lee, JJ; Kim, JS; Min, CK; Kim, K; Choi, Y; Eom, HS; Joo, YD; Kim, SH; Kwak, JY; Kang, HJ; Lee, JH; Lee, HS; Mun, YC; Moon, JH; Sohn, SK; Park, SK; Park, Y; Shin, HJ; Yoon, SS

KOREAN J RADIOL 2018 10.3348/kjr.2018.19.3.481
Prognostic Value of Baseline F-18-Fluorodeoxyglucose PET/CT in Patients with Multiple Myeloma: A Multicenter Cohort Study
Moon1, SH; Choi, WH; Yoo, IR; Lee, SJ; Paeng, JC; Jeong, SY; Lee, SW; Kim, K; Choi, JY

ANN LAB MED 2018 10.3343/alm.2018.38.3.196
Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience
Jung1, HA; Jang, MA; Kim, K; Kim, SH

ANN ONCOL 2018 10.1093/annonc/mdy034
Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+gastric cancer patients
Kim1, ST; Banks, KC; Pectasides, F; Kim, SY; Kim, K; Lanman, RB; Talasaz, A; An, J; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, NKD; Park, W; Lee, H; Bass, AJ; Kim, K; Kang, WK; Lee, J

AM J HEMATOL 2017 10.1002/ajh.24891
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy
Cho1, H; Yoon, DH; Lee, JB; Kim, SY; Moon, JH; Do, YR; Lee, JH; Park, Y; Lee, HS; Eom, HS; Shin, HJ; Min, CK; Kim, JS; Jo, JC; Kang, HJ; Mun, YC; Lee, WS; Lee, JJ; Suh, C; Kim, K

JPN J CLIN ONCOL 2017 10.1093/jjco/hyx120
Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy
Park1, JS; Lim, DH; Ahn, YC; Park, W; Kim, SJ; Kim, WS; Kim, K

LEUKEMIA 2017 10.1038/leu.2017.138
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
Kumar1, SK; Dimopoulos, MA; Kastritis, E; Terpos, E; Nahi, H; Goldschmidt, H; Hillengass, J; Leleu, X; Beksac, M; Alsina, M; Oriol, A; Cavo, M; Ocio, EM; Mateos, MV; O'Donnell, EK; Vij, R; Lokhorst, HM; van de Donk, NWCJ; Min, C; Mark, T; Turesson, I; Hansson, M; Ludwig, H; Jagannath, S; Delforge, M; Kyriakou, C; Hari, P; Mellqvist, U; Usmani, SZ; Dytfeld, D; Badros, AZ; Moreau, P; Kim, K; Otero, PR; Lee, JH; Shustik, C; Waller, D; Chng, WJ; Ozaki, S; Lee, JJ; de la Rubia, J; Eom, HS; Rosinol, L; Lahuerta, JJ; Sureda, A; Kim, JS; Durie, BGM

ONCOTARGET 2017 10.18632/oncotarget.18535
The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160)
Jung1, SH; Lee, JJ; Kim, K; Suh, C; Yoon, DH; Min, CK; Sohn, SK; Choi, CW; Lee, HS; Kim, HJ; Shin, HJ; Bang, SM; Yoon, SS; Park, SK; Yhim, HY; Kim, MK; Jo, JC; Mun, YC; Lee, JH; Kim, JS

Clin Transl Oncol 2017 10.1007/s12094-017-1662-x
Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma
Cho1, J; Kim, SY; Kim, YJ; Sim, MH; Kim, ST; Kim, NKD; Kim, K; Park, W; Kim, JH; Jang, KT; Lee, J

Nutrition. 2017 Apr;36:67-71. doi: 10.1016/j.nut.2016.06.009. Epub 2016 Jun 25.
Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma
Kim HS11, Lee JY2, Lim SH2, Cho J3, Kim SJ2, Jang JH2, Kim WS2, Jung CW2, Kim K4.

Br J Haematol. 2017 Mar;176(5):743-749. doi: 10.1111/bjh.14465. Epub 2017 Jan 20.
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial
Lu J11, Lee JH2, Huang SY3, Qiu L4, Lee JJ5, Liu T6, Yoon SS7, Kim K8, Shen ZX9, Eom HS10, Chen WM11, Min CK12, Kim HJ13, Lee JO14, Kwak JY15, Yiu W16, Chen G16, Ervin-Haynes A16, Hulin C17, Facon T18.

Cancer Med. 2017 Jan;6(1):100-108. doi: 10.1002/cam4.970. Epub 2016 Dec 1.
Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study
Kwon J11, Min CK2, Kim K3, Han JJ4, Moon JH5, Kang HJ6, Eom HS7, Kim MK8, Kim HJ9, Yoon DH10, Lee JO11, Lee WS12, Lee JH13, Lee JJ14, Choi YS15, Kim SH16, Yoon SS17.

J Infect. 2016 Nov;73(5):496-505. doi: 10.1016/j.jinf.2016.06.011. Epub 2016 Jul 7.
Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients
Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Chung DR2, Kang CI2, Peck KR2, Jung CW3.

Oncotarget. 2016 Oct 18;7(42):68350-68359. doi: 10.18632/oncotarget.12029.
Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis
Kim SJ11, Shin HT2, Lee HO2, Kim NK2, Yun JW2, Hwang JH3, Kim K1, Park WY2.

Oncotarget. 2016 Sep 13;7(37):59892-59901. doi: 10.18632/oncotarget.10988.
Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation
Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Jung CW1.

BMC Cancer. 2016 Aug 8;16:613. doi: 10.1186/s12885-016-2645-y.
Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen
Jung SH11, Cho MS1, Kim HK2, Kim SJ2, Kim K3, Cheong JW4, Kim SJ4, Kim JS4, Ahn JS1, Kim YK1, Yang DH1, Kim HJ1, Lee JJ5; Korean Multiple Myeloma Working Party (KMMWP).

Oncotarget. 2016 Jul 26;7(30):47127-47133. doi: 10.18632/oncotarget.9478.
Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker
Ryu D11,2, Kim HJ3, Joung JG1, Lee HO1,4, Bae JS1, Kim SJ5, Kim H5, Park WY1,2,4, Kim K5.

Ann Hematol. 2016 May;95(6):911-9. doi: 10.1007/s00277-016-2660-8. Epub 2016 Apr 6.
The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea
Lee HS11, Min CK2, Lee JJ3, Kim K4, Kim SJ4, Yoon DH5, Eom HS6, Lee H6, Lee WS7, Shin HJ8, Lee JH9, Park Y10, Jo JC11, Do YR12, Mun YC13, Lee MH14

J Infect. 2016 Feb;72(2):233-9. doi: 10.1016/j.jinf.2015.10.014. Epub 2015 Nov 26.
Multiple myeloma as a major cause of false-positive galactomannan tests in adult patients with cancer
Ko JH11, Peck KR2, Lee JY1, Cho SY1, Ha YE1, Kang CI1, Chung DR1, Kim K3, Kang ES4, Song JH1.

Ann Hematol. 2016 Jan;95(2):325-35. doi: 10.1007/s00277-015-2523-8. Epub 2015 Oct 10.
Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis
Lim SH11, Park S1, Jang JH1, Kim K1, Kim HJ2, Kim SH2, Kang CI3, Chung DR3, Peck KR3, Lee J4, Cha HS4, Koh EM4, Ko YH5, Kim WS1, Jung CW1, Kim SJ6,7.

Oncotarget. 2015 Dec 15;6(40):42803-12. doi: 10.18632/oncotarget.5658.
Iron deficient erythropoiesis might play key role in development of anemia in cancer patients
Park S11, Jung CW1, Kim K1, Kim SJ1, Kim WS1, Jang JH1.

Liver Int. 2015 Nov;35(11):2363-9. doi: 10.1111/liv.12838. Epub 2015 Apr 12.
Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy
Lee JY11, Lim SH1, Lee MY1, Kim H1, Sinn DH1, Gwak GY1, Choi MS1, Lee JH1, Jung CW1, Jang JH1, Kim WS1, Kim SJ1, Kim K1.

J Clin Lab Anal. 2015 Nov;29(6):505-10. doi: 10.1002/jcla.21801. Epub 2014 Oct 2.
Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma
Shin SY11, Lee ST1, Kim HJ1, Kim SJ2, Kim K2, Kang ES1, Kim SH1.

Transpl Infect Dis. 2015 Oct;17(5):679-87. doi: 10.1111/tid.12424. Epub 2015 Sep 26.
Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma
Park S11, Jung CW1, Jang JH1, Kim SJ1, Kim WS1, Kim K1.

Korean J Intern Med. 2015 Sep;30(5):675-83. doi: 10.3904/kjim.2015.30.5.675. Epub 2015 Aug 28.
The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
Kim C11, Lee HS1, Min CK2, Lee JJ3, Kim K4, Yoon DH5, Eom HS6, Lee H6, Lee WS7, Shin HJ8, Lee JH9, Park Y10, Jo JC11, Do YR12, Mun YC13.

J Hematol Oncol. 2015 Sep 4;8:103. doi: 10.1186/s13045-015-0198-1.
Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study
Gupta N11, Goh YT2, Min CK3, Lee JH4, Kim K5, Wong RS6, Chim CS7, Hanley MJ8, Yang H9, Venkatakrishnan K10, Hui AM11, Esseltine DL12, Chng WJ13,14.

Hum Immunol. 2015 Sep;76(9):636-43. doi: 10.1016/j.humimm.2015.09.009. Epub 2015 Sep 25.
KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study
Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Kang ES2, Jung CW3.

Blood. 2015 Aug 6;126(6):746-56. doi: 10.1182/blood-2015-03-636548. Epub 2015 Jun 11.
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia
Kim DY1, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, Kim DH, Kim K, Jung CW, Kim I, Yoon SS, Park S, Ahn JS, Yang DH, Lee JJ, Lee HS, Kim YS, Mun YC, Kim H, Park JH, Moon JH, Sohn SK, Lee SM, Lee WS, Kim KH, Won JH, Hyun MS, Park J, Lee JH, Shin HJ, Chung JS, Lee H, Eom HS, Lee GW, Cho YU, Jang S, Park CJ, Chi HS, Lee KH; Adult Acute Lymphoblastic Leukemia Working Party of the Korean Society of Hematology.

Korean J Intern Med. 2015 Jul;30(4):496-505. doi: 10.3904/kjim.2015.30.4.496. Epub 2015 Jun 29.
Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience
Lim AY11, Lee JH1, Jung KS1, Gwag HB1, Kim do H1, Kim SJ1, Lee GY1, Kim JS2, Kim HJ3, Lee SY3, Lee JE1, Jeon ES1, Kim K1.

Anticancer Res. 2015 May;35(5):3081-9.
Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome
Hong JY11, Seo JY2, Kim SH3, Jung HA4, Park S4, Kim K4, Jung CW4, Kim JS5, Park JS6, Kim HJ7, Jang JH8.

Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):227-35. doi: 10.1016/j.clml.2014.12.007. Epub 2014 Dec 12.
The t(11;14)(q13;q32) Trans location as a Poor Prognostic Parameter for Autologous Stem Cell Transplantation in Myeloma Patients With Extramedullary Plasmacytoma
Shin HJ11, Kim K2, Lee JJ3, Song MK1, Lee EY4, Park SH4, Kim SH5, Jang MA5, Kim SJ6, Chung JS1.

Ann Hum Genet. 2015 Mar;79(2):99-107. doi: 10.1111/ahg.12101. Epub 2015 Jan 23.
Asp58Ala is the Predominant Mutation of the TTR Gene in Korean Patients with Hereditary Transthyretin-Related Amyloidosis
Jang MA11, Lee GY, Kim K, Kim SJ, Kim JS, Lee SY, Kim HJ, Jeon ES.

Amyloid. 2014 Dec;21(4):261-6. doi: 10.3109/13506129.2014.960560. Epub 2014 Sep 24.
Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis
Lee JY11, Lim SH, Kim SJ, Lee GY, Lee JE, Choi JO, Kim JS, Kim HJ, Lee SY, Min JH, Jeon ES, Kim K.

Vox Sang. 2014 Nov;107(4):407-15. doi: 10.1111/vox.12183. Epub 2014 Jul 31.
Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience
Lee KH11, Jung SK, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW, Kim DW, Kang ES.

Eur J Haematol. 2014 Nov;93(5):414-21. doi: 10.1111/ejh.12377. Epub 2014 Jun 14.
Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma
Shin HJ11, Kim K, Lee JW, Song MK, Lee JJ, Lee HS, Lee WS, Kim SJ, Chung JS.

Support Care Cancer. 2014 Oct;22(10):2669-75. doi: 10.1007/s00520-014-2256-6. Epub 2014 Apr 26.
Impact of dose modification on intravenous Bortezomib-induced peripheral neuropathy in multiple myeloma patients
Cho J11, Kang D, Lee JY, Kim K, Kim SJ.

Leuk Lymphoma. 2014 Oct;55(10):2395-7. doi: 10.3109/10428194.2014.880429. Epub 2014 Mar 7.
Spinal cord compression in multiple myeloma: a single center experience
Jung HA11, Cho SH, Kim SJ, Jang JH, Kim WS, Jung CW, Kim K.

Ann Hematol. 2014 Sep;93(9):1571-7. doi: 10.1007/s00277-014-2067-3. Epub 2014 Apr 12.
Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study
Ahn SY11, Jung SH, Joo YD, Lee WS, Lee SM, Choi CW, Kim SJ, Kim K, Lee JJ; Korean Multiple Myeloma Working Party.

Ann Hematol. 2014 Aug;93(8):1353-61. doi: 10.1007/s00277-014-2057-5. Epub 2014 Mar 27.
Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study
Oh S11, Koo DH, Kwon MJ, Kim K, Suh C, Min CK, Yoon SS, Shin HJ, Jo DY, Kwak JY, Kim JS, Sohn SK, Joo YD, Eom HS, Kim SH, Kim YS, Kim C, Mun YC, Kim H, Lee DS, Lee JH; Korean Multiple Myeloma Working Party (KMMWP).

Acta Haematol. 2014;132(2):226-32.
Thalidomide, Cyclophosphamide and Dexamethasone Induction Therapy: Feasibility for Myeloma Patients Destined for Autologous Stem Cell Transplantation
Chang WJ1, Kang ES, Lee ST, Kim SH, Kim DW, Kim SJ, Kim K.

Ann Hematol. 2014 Aug;93(8):1353-61. doi: 10.1007/s00277-014-2057-5. Epub 2014 Mar 27.
Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study
Oh S11, Koo DH, Kwon MJ, Kim K, Suh C, Min CK, Yoon SS, Shin HJ, Jo DY, Kwak JY, Kim JS, Sohn SK, Joo YD, Eom HS, Kim SH, Kim YS, Kim C, Mun YC, Kim H, Lee DS, Lee JH; Korean Multiple Myeloma Working Party (KMMWP).

Anticancer Res. 2014 Aug;34(8):4299-306.
Renal Insufficiency in Newly-diagnosed Multiple Myeloma: Analysis According to International Myeloma Working Group Consensus Statement
Park S11, Han B2, Kim K3, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.

Am J Hematol. 2014 Jul;89(7):751-6. doi: 10.1002/ajh.23731. Epub 2014 Apr 26.
Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study
Kim K11, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, Chou T, Kosugi H, Suzuki K, Chen W, Hou J, Lu J, Huang XJ, Huang SY, Chng WJ, Tan D, Teoh G, Chim CS, Nawarawong W, Siritanaratkul N, Durie BG.

Biomed Res Int. 2014;2014:437852. doi: 10.1155/2014/437852. Epub 2014 Jul 10.
Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma
Kim SM11, Kim MJ1, Jung HA1, Kim K1, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.

Biomed Res Int. 2014;2014:253243. doi: 10.1155/2014/253243. Epub 2014 Jun 4.
Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenstrom Macroglobulinemia in Korea
Lee HS11, Kim K2, Yoon DH3, Kim JS4, Bang SM5, Lee JO5, Eom HS6, Lee H6, Kim I7, Lee WS8, Bae SH9, Kim SH10, Lee MH11, Do YR12, Lee JH13, Hong J13, Shin HJ14, Lee JH15, Mun YC16, Min CK17.

Mayo Clin Proc.?2014 Jun;89(6):781-9. doi: 10.1016/j.mayocp.2014.01.013. Epub 2014 Apr 3.
Cardiac Amyloidosis Without Increased Left Ventricular Wall Thickness
Lee GY11,?Kim K2,?Choi JO1,?Kim SJ2,?Kim JS3,?Choe YH4,?Grogan MA5,?Jeon ES6.

Acta Haematol. 2014;131(4):193-9. doi: 10.1159/000354839. Epub 2013 Nov 26.
Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients
Park S11, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Jung CW, Jang JH, Kim SJ, Kim WS, Choi JY, Kim K.

Ann Hematol. 2014 Apr;93(4):603-8. doi: 10.1007/s00277-013-1915-x. Epub 2013 Oct 19.
Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts
Seo JY11, Lee KO, Kim SH, Kim K, Jung CW, Jang JH, Kim HJ.

Br J Haematol. 2014 Mar;164(5):745-8. doi: 10.1111/bjh.12670. Epub 2013 Nov 18.
Central nervous system multiple myeloma: a different cytogenetic profile
Chang WJ11, Kim SJ, Kim K.

Anticancer Res. 2014 Feb;34(2):1037-45.
Prognostic Factor Analysis in Core-Binding Factor-positive Acute Myeloid Leukemia
Jung HA11, Maeng CH, Park S, Kim SJ, Kim K, Jang JH, Jung CW.

Ann Hematol. 2014 Jan;93(1):113-21. doi: 10.1007/s00277-013-1893-z. Epub 2013 Sep 12.
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients
Kim K11, Kim SJ, Voelter V, Suh C, Yoon SS, Lee JJ, Kwak JY, Ryoo HM, Kim YS, Moon JH, Park SK, Kim SH, Mun YC, Kim JS, Eom HS, Jo DY, Jun HJ, Kim KH, Lee JO, Lee JH, Min CK; Korean Multiple Myeloma Working Party (KMMWP).

Ann Hematol. 2014 Jan;93(1):99-105. doi: 10.1007/s00277-013-1952-5. Epub 2013 Nov 16.
DCEP for relapsed or refractory multiple myeloma after therapy with novel agents
Park S11, Lee SJ, Jung CW, Jang JH, Kim SJ, Kim WS, Kim K.

Amyloid. 2013 Dec;20(4):204-11. doi: 10.3109/13506129.2013.824417. Epub 2013 Aug 5.
Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea
Kim SJ11, Lee GY, Jang HR, Choi JO, Kim JS, Kim HJ, Lee SY, Min JH, Jeon ES, Kim K.

Leuk Res. 2013 Sep;37(9):1070-6. doi: 10.1016/j.leukres.2013.06.008. Epub 2013 Jun 28.
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network
Tan D11, Kim K, Kim JS, Eom HS, Teoh G, Ong KH, Goh YT, Durie BG, Chng WJ, Lee JH.

Bone Marrow Transplant. 2013 Mar;48(3):425-32. doi: 10.1038/bmt.2012.164. Epub 2012 Sep 3.
Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT
Yhim HY11, Kim K, Kim JS, Kang HJ, Kim JA, Min CK, Bae SH, Park E, Yang DH, Suh C, Kim MK, Mun YC, Eom HS, Shin HJ, Yoon HJ, Kwon JH, Lee JH, Kim YS, Yoon SS, Kwak JY.

Am J Hematol. 2013 Jan;88(1):52-5. doi: 10.1002/ajh.23333. Epub 2012 Oct 1.
Clinical features and treatment outcome of primary systemic light-chain amyloidosis in Korea: Results of multicenter analysis
Jun HJ11, Kim K, Kim SJ, Mun YC, Bang SM, Won JH, Kim CS, Lee JH; Korean Multiple Myeloma Working Party (KMMWP).

J Korean Med Sci. 2013 Jan;28(1):80-6. doi: 10.3346/jkms.2013.28.1.80. Epub 2013 Jan 8.
Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation
Lee HS11, Kim YS, Kim K, Kim JS, Kim HJ, Min CK, Suh C, Eom HS, Yoon SS, Lee JH, Kim MK, Kim SH, Bae SH, Mun YC, Jo DY, Chung JS; Korean Multiple Myeloma Working Party (KMMWP).

Clin Lymphoma Myeloma Leuk. 2012 Apr;12(2):118-26. doi: 10.1016/j.clml.2011.11.002. Epub 2011 Dec 28.
Lower Dose Dexamethasone/Thalidomide and Zoledronic Acid Every 3 Weeks in Previously Untreated Multiple Myeloma
Teoh G11, Chen Y, Kim K, Srivastava A, Pai VR, Yoon SS, Suh C, Kim YK.

Ann Hematol. 2012 Feb;91(2):249-56. doi: 10.1007/s00277-011-1298-9. Epub 2011 Jul 26.
Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial
Kim HJ11, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH.

Am J Hematol. 2012 Jan;87(1):37-41. doi: 10.1002/ajh.22193. Epub 2011 Nov 25.
Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity
Ahn HK11, Jang JH, Kim K, Kim HJ, Kim SH, Jung CW, Kim DH.

Biol Blood Marrow Transplant. 2011 Nov;17(11):1630-7. doi: 10.1016/j.bbmt.2011.04.006. Epub 2011 Apr 23.
Changes of Hepatitis B Virus Serologic Status after Allogeneic Hematopoietic Stem Cell Transplantation and Impact of Donor Immunity on Hepatitis B Virus
Park S11, Kim K, Kim DH, Jang JH, Kim SJ, Kim WS, Jung CW, Koh KC.

Jpn J Clin Oncol. 2011 Mar;41(3):353-7. doi: 10.1093/jjco/hyq194. Epub 2010 Oct 14.
Low-dose Acyclovir is Effective for Prevention of Herpes Zoster in Myeloma Patients Treated with Bortezomib: A Report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study
Kim SJ11, Kim K, Do YR, Bae SH, Yang DH, Lee JJ.

Ann Oncol. 2011 Feb;22(2):411-6. doi: 10.1093/annonc/mdq393. Epub 2010 Aug 2.
Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients
Kim MK11, Suh C, Lee DH, Min CK, Kim SJ, Kim K, Moon JH, Yoon SS, Lee GW, Kang HJ, Kim SH, Choi CW, Eom HS, Kwak JY, Kim HJ, Mun YC, Bang SM, Lee K, Shin HJ, Lee JH; Korean Multiple Myeloma Working Party.

Ann Hematol. 2010 Sep;89(9):905-12. doi: 10.1007/s00277-010-0943-z. Epub 2010 Mar 27.
Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety
Lee SS11, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, Do YR, Jin JY, Kang HJ, Lee GW, Lee MH, Shim H, Kim K, Yoon SS, Bang SM, Kim HY, Lee JJ, Park J, Lee DS, Lee JH; Korean Multiple Myeloma Working Party.

Int J Hematol. 2010 Jul;92(1):52-7. doi: 10.1007/s12185-010-0617-6. Epub 2010 Jun 11.
Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party
Lee JH11, Lee DS, Lee JJ, Chang YH, Jin JY, Jo DY, Bang SM, Kim HJ, Kim JS, Kim K, Eom HS, Min CK, Yoon SS, Kim SH, Suh C, Cho KS; Korean Multiple Myeloma Working Party.

Int J Hematol. 2010 Jun;91(5):886-91. doi: 10.1007/s12185-010-0580-2. Epub 2010 May 8.
A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation
Kim ST11, Lee MH, Kim SY, Kim SJ, Kim DH, Jang JH, Kim K, Kim WS, Jung CW.

Ann Hematol. 2010 May;89(5):489-97. doi: 10.1007/s00277-009-0871-y. Epub 2009 Dec 10.
Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP)
Eom HS11, Kim YK, Chung JS, Kim K, Kim HJ, Kim HY, Jin JY, Do YR, Oh SJ, Suh C, Seong CM, Kim CS, Lee DS, Lee JH.

Br J Haematol. 2010 May;149(4):537-49. doi: 10.1111/j.1365-2141.2010.08127.x. Epub 2010 Mar 12.
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
Kim K11, Kong SY, Fulciniti M, Li X, Song W, Nahar S, Burger P, Rumizen MJ, Podar K, Chauhan D, Hideshima T, Munshi NC, Richardson P, Clark A, Ogden J, Goutopoulos A, Rastelli L, Anderson KC, Tai YT.

Cancer Genet Cytogenet. 2010 Mar;197(2):117-21. doi: 10.1016/j.cancergencyto.2009.11.008.
Molecular cytogenetic analysis of Korean patients with Waldenstrom macroglobulinemia
Bang SM11, Seo JW, Park KU, Kim SJ, Kim K, Kim SH, Cho SR, Kim HC, Song J, Kim JS, Kim KH, Lee JH, Lee JJ, Shin MG, Suh C, Chi HS, Oh DY, Won JH, Kim HJ, Yoon SS, Lee DS; Korean Multiple Myeloma Working Party (KMMWP).

Leuk Res. 2010 Feb;34(2):166-72. doi: 10.1016/j.leukres.2009.05.009. Epub 2009 Jun 10.
BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients
Moon JH11, Sohn SK, Lee MH, Jang JH, Kim K, Jung CW, Kim DH.

Ann Hematol. 2010 Feb;89(2):201-6. doi: 10.1007/s00277-009-0807-6. Epub 2009 Aug 25.
Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide
Koh Y11, Bang SM, Lee JH, Yoon HJ, Do YR, Ryoo HM, Lee N, Kim SJ, Kim K, Yoon SS, Won JH, Mun YC, Lee MH, Rhee KH, Kim HJ, Eom H, Kim MK, Shin HC; Korean Multiple Myeloma Working Party.

J Clin Oncol. 2010 Feb 1;28(4):e54-5. doi: 10.1200/JCO.2009.23.7560. Epub 2009 Nov 16.
Gastric Recurrence of Extramedullary Granulocytic Sarcoma After Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
Choi ER11, Ko YH, Kim